Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD? Finerenone + SGLT2 Inhibitor of Benefit in Diabetes With CKD?

Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors in patients with type 2 diabetes.Medscape Medical News

Source: Medscape Cardiology Headlines - February 28, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news